SENSOME
21.6.2021 08:02:06 CEST | Business Wire | Press release
Sensome, the company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today that it has been granted a Breakthrough Device designation by the Center of Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for its Clotild® Smart Guidewire System designed to improve the treatment of ischemic stroke patients.
Acute ischemic stroke, a leading cause of long-term disability, can be treated by removing the clot blocking the brain blood vessel using mechanical thrombectomy devices, which are guided from the groin over a wire to the blockage. To improve patient prognosis, the clot needs to be removed as fast as possible. Today, without knowledge of the clot’s characteristics, the clot can only be removed on the first attempt in one out of three cases. Clotild® Smart Guidewire System integrating Sensome’s AI-powered tissue sensor enables the guidewire to provide physicians with critical information on the clot.
The FDA Breakthrough Device Program is intended to help patients receive more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions. As part of this program, the FDA will provide Sensome with priority review and interactive communication on its path from device development to commercialization.
“This is a tremendous recognition by FDA that will boost our efforts to bringing Clotild® to patients in the US,” indicates Franz Bozsak, CEO and co-founder of Sensome, “The first-in-human clinical trial of Clotild® is expected to start later this year outside the United States, which will take our device one step closer to improving care for ischemic stroke patients around the world.”
About Sensome
Sensome, a spin-off from CNRS and Ecole polytechnique (France), has developed a revolutionary sensor technology that turns invasive medical devices into connected healthcare devices. The company’s sensing technology combines impedance-based micro-sensors with machine learning algorithms to instantly identify biological tissues with unequaled predictive reliability. Its first application is the Clotild®
connected guidewire for the treatment of ischemic stroke. Sensome's sensor technology can be deployed in multiple other medical fields, such as interventional cardiology and oncology.
www.sensome.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210620005074/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Real Asset Acquisition Corp. Announce Effectiveness of Registration Statement for Proposed Business Combination8.6.2026 16:16:00 CEST | Press release
RAAQ Extraordinary General Meeting Scheduled for June 25, 2026 IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced today that the registration statement on Form F-4 (the “Registration Statement”), relating to their previously announced business combination, has been declared effective by the U.S. Securities and Exchange Commission (“SEC”) on June 5, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608520188/en/ IQM Radiance quantum computer The extraordinary general meeting of RAAQ’s shareholders in connection with the proposed business combination (the “Extraordinary General Meeting”) will be held on June 25, 2026. The proxy statement/prospectus relating to the Extraordinary General Meeting was mailed to RAAQ’s shareholders of record
Monster Hunter Wilds: Ascendance to Launch in 2027!8.6.2026 15:00:00 CEST | Press release
– Monster Hunter: World, released in 2018, surpassed 30 million units as Capcom looks to expand its global user base – Capcom Co., Ltd. (TOKYO:9697) today announced that Monster Hunter Wilds: Ascendance, a massive expansion for Monster Hunter Wilds, is scheduled for release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608183725/en/ Monster Hunter Wilds Ascendance key art Monster Hunter Wilds: Ascendance is a massive expansion (paid content) for Monster Hunter Wilds, which was released in February 2025. As a continuation of the main game’s story, the expansion will further deepen the gameplay experience with new content including new quest ranks, locales, additional monsters and expanded weapon actions through new gameplay features. The company is currently developing the title for release in 2027. Capcom is also developing Monster Hunter Wilds for Nintendo Switch™ 2 in addition to the existing platforms. Furthe
Resident Evil Veronica to Launch in 2027!8.6.2026 15:00:00 CEST | Press release
– Capcom aims to further enhance the IP’s value by remaking a popular title of the series – Capcom Co., Ltd. (TOKYO:9697) today announced that Resident Evil Veronica, the latest title in the Resident Evil series, is scheduled for release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608994346/en/ Resident Evil Veronica key art The Resident Evil franchise features survival horror games in which players utilize a variety of weapons and other items to survive terrifying situations. Supported by a passionate global fanbase, cumulative game sales since the first title in this flagship series debuted in 1996 exceed 201 million* units. Resident Evil Veronica is a remake of the original Resident Evil Code: Veronica, released in the year 2000. While preserving the appeal of the original, Capcom is developing the 2027 release as the latest installment of the Resident Evil series, with a reimagined story and high-quality g
Neuraptive Therapeutics, Inc. Announces Key Organizational Updates to Support the Company’s Advancement Toward Commercialization8.6.2026 15:00:00 CEST | Press release
Ulf Wiinberg appointed to Board of DirectorsWilliam “Bill” MacKenzie hired as Senior Vice President – Finance Neuraptive Therapeutics today announced the appointment of Ulf Wiinberg to its Board of Directors and William “Bill” MacKenzie as Senior Vice President – Finance. Mr. Wiinberg is a seasoned biotechnology, pharmaceutical and healthcare industries executive with an extensive global career. As a member of the Board of Directors, he will contribute strategic guidance and industry expertise to support the Company’s development and commercialization strategy. Mr. Wiinberg’s experience includes serving as CEO of X-Vax Technology, Inc. from 2017 until 2024 and prior to that, he was CEO of Lundbeck from 2008 until 2014. From 2002 to 2008, he was a member of Wyeth’s Management Committee and during this time, he was Worldwide President of Wyeth Consumer Healthcare from 2002 to 2005, and President of Europe/Middle East/Africa until 2008, when Wyeth was acquired by Pfizer. Ulf serves as a d
Xylem Expands Long-Term Water Partnership with Dow8.6.2026 14:00:00 CEST | Press release
Agreement to design, build and operate advanced water solution Project to advance integrated water reuse capability, significantly reducing freshwater demand Xylem (NYSE: XYL), a leading global water technology company, today announced a landmark agreement with Dow (NYSE: DOW) to design, build and operate advanced water systems at its large-scale industrial complex in Fort Saskatchewan, Alberta, Canada. The agreement expands Xylem’s long-standing collaboration with Dow, supporting the increased operations tied to Dow’s Path2Zero project. Under the agreement, Xylem will deliver a full end-to-end solution that includes engineering, system design, and long-term operation. The project is designed to support reliable, high-quality water supply, treatment, and reuse across the site. The system is expected to be operational by August 2028. “This agreement represents a major milestone for Xylem,” said Rodney Aulick, EVP and President, Water Solutions and Services at Xylem. “It reflects the str
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom